Fibromyalgia

Last updated: June 19, 2025

Fibromyalgia

IM EOR

IM EOR

Angina pectoris
Premature atrial contraction
Premature ventricular contraction
Supraventricular arrhythmias: Pathology review
Ventricular tachycardia
Ventricular fibrillation
Atrial flutter
Atrial fibrillation
Wolff-Parkinson-White syndrome
Atrioventricular nodal reentrant tachycardia (AVNRT)
Long QT syndrome and Torsade de pointes
Stable angina
Unstable angina
Prinzmetal angina
Class I antiarrhythmics: Sodium channel blockers
Dilated cardiomyopathy
Hypertrophic cardiomyopathy
Restrictive cardiomyopathy
Heart failure
Diabetes mellitus
Hypoglycemics: Insulin secretagogues
Miscellaneous hypoglycemics
Insulins
Diabetes insipidus
Hypercalcemia
Hypocalcemia
Hypernatremia
Hyponatremia
Hyperparathyroidism
Hypoparathyroidism
Hypercholesterolemia: Clinical
Lipid-lowering medications: Statins
Coronary artery disease: Clinical
Endocarditis
Class II antiarrhythmics: Beta blockers
Peptic ulcer
Acute pancreatitis
Chronic pancreatitis
GERD, peptic ulcers, gastritis, and stomach cancer: Pathology review
Gastritis
Thiazide and thiazide-like diuretics
ACE inhibitors, ARBs and direct renin inhibitors
ECG cardiac infarction and ischemia
Abnormal heart sounds
Pulmonary valve disease
Tricuspid valve disease
cGMP mediated smooth muscle vasodilators
Sarcoidosis
Mycobacterium tuberculosis (Tuberculosis)
Pneumonia
Myocardial infarction
Adrenergic antagonists: Beta blockers
Hyperthyroidism
Hypothyroidism
Thyroid storm
Hypertension: Clinical
Class IV antiarrhythmics: Calcium channel blockers and others
Calcium channel blockers
Asthma
Emphysema
Pericarditis and pericardial effusion
Cardiac tamponade
Antiplatelet medications
Primary adrenal insufficiency
Pheochromocytoma
Cushing syndrome
Ischemic stroke
Bell palsy
Multiple sclerosis
Guillain-Barre syndrome
Bundle branch block
Migraine
Tension headache
Cluster headache
Syncope: Clinical
Transient ischemic attack
Non-steroidal anti-inflammatory drugs
Fibromyalgia
Gout
Systemic lupus erythematosus
Iron deficiency anemia
Lipid-lowering medications: Fibrates
Miscellaneous lipid-lowering medications
Pulmonary hypertension
Pneumothorax
Lung cancer
Pulmonary embolism
Pseudomonas aeruginosa
Clostridium botulinum (Botulism)
Vitamin B12 deficiency
Influenza virus
Sickle cell disease (NORD)
Treponema pallidum (Syphilis)
Clostridium tetani (Tetanus)
Borrelia burgdorferi (Lyme disease)
Protein C deficiency
Folate (Vitamin B9) deficiency
Factor V Leiden
Protein S deficiency
Antithrombin III deficiency
Glucose-6-phosphate dehydrogenase (G6PD) deficiency
Paget disease of bone
Antiphospholipid syndrome
Rheumatoid arthritis
Ulcerative colitis
Candida
Cryptococcus neoformans
Positive and negative predictive value
Cirrhosis
Thyroid cancer
Shock
Neisseria gonorrhoeae
Pituitary adenoma
Seizures and epilepsy
Bordetella pertussis (Whooping cough)
Prostatitis
Meningitis
Vibrio cholerae (Cholera)
Testicular torsion
Epididymitis
Polycystic kidney disease
Polymyalgia rheumatica
Polymyositis
Hemorrhoid
Portal hypertension
Varicocele
Varicella zoster virus
Irritable bowel syndrome
Cytomegalovirus
Acid reducing medications
Concussion and traumatic brain injury
Hepatocellular carcinoma
Renal artery stenosis
Rheumatic heart disease
Cor pulmonale
Gastroesophageal reflux disease (GERD)
Sjogren syndrome
Huntington disease
Scleroderma
Acute cholecystitis
Viral hepatitis
Appendicitis
Diverticulosis and diverticulitis
Kidney stones
Acute pyelonephritis
Chronic pyelonephritis
Lower urinary tract infection
Glaucoma
Ascending cholangitis
Non-urothelial bladder cancers
Hydronephrosis
Celiac disease
Benign prostatic hyperplasia
Prerenal azotemia
Renal azotemia
Postrenal azotemia
Chronic kidney disease
Poststreptococcal glomerulonephritis
Membranous nephropathy
Membranoproliferative glomerulonephritis
IgA nephropathy (NORD)
Acute tubular necrosis
Acute kidney injury: Clinical
Chronic kidney disease: Clinical
Alport syndrome
Parkinson disease
Encephalitis
Delirium
Dementia with Lewy bodies
Vascular dementia
Frontotemporal dementia
Alzheimer disease
Adult brain tumors
Acid-base map and compensatory mechanisms
Erectile dysfunction
Acromegaly
Esophageal web
Esophageal disorders: Clinical
Colorectal cancer
Rapidly progressive glomerulonephritis
Goodpasture syndrome
Esophageal cancer
Gastric cancer
Esophagitis: Clinical
HIV (AIDS)
Anemia of chronic disease
Beta-thalassemia
Anemia of chronic disease
Alpha-thalassemia
Multiple myeloma
Shigella
Toxoplasma gondii (Toxoplasmosis)
Histoplasmosis
Rickettsia rickettsii (Rocky Mountain spotted fever) and other Rickettsia species
Pneumonia: Clinical

Transcript

Watch video only

The term fibromyalgia can be broken down. Fibro- refers to fibrous tissue, -my- refers to muscle and -algia refers to pain.

Fibromyalgia is a chronic condition, which occurs more often in women, that causes widespread muscle pain, extreme tenderness in various parts of the body, and sleep disturbances.

Normally, if a person cuts their finger, a specific type of sensory neuron called a nociceptor or pain receptor, converts that stimulus into an electrical signal.

These are the first neurons and they’re primarily found in the skin, joints, or the walls of organs.

The electrical signal goes from the dendrite of the nociceptor into its peripheral axon branch and heads up the hand and arm towards its cell body.

The cell body is located in the dorsal root ganglion which is a cluster of nerve cell bodies located in a dorsal root of the spinal nerve.

The dorsal root ganglia contains the cell bodies of many sensory neurons that receive information.

So in this case, the cell body would receive the electrical signal, and if it’s strong enough, it would start to release substance P, which is a small chemical involved in pain perception.

Substance P would go down the other axon branch of the nociceptor and would get released from the neuron’s terminal button.

Substance P then binds to receptors on a second neuron which has its cell body located in the dorsal horn of the spinal cord, which makes up the back portion of the spinal cord that receives sensory information.

There is also a separate group of neurons called inhibitory neurons in the spinal cord that dampen or reduce the pain response, counteracting the effect of nociceptors.

These inhibitory neurons release neurotransmitters such as serotonin and norepinephrine and they also act on the second neuron in the spinal cord to inhibit the pain signal.

If the signal from the nociceptors is greater than the signal from the inhibitory neurons, then it triggers the second neuron in the spinal cord to fire an action potential.

This electrical signal goes all the way up the spinal cord to the brain where the pain is perceived.

So while, the pain signal races towards the brain, important events are happening in the damaged finger as well.

Epithelial cells near the damaged area start to release nerve growth factor.

That nerve growth attracts nearby mast cells which start to release even more nerve growth factor - amplifying the effect.

The high levels of nerve growth factor do a few important things to nociceptors.

It boosts the growth, makes them more sensitive to pain, and makes them produce even more substance P.

In fibromyalgia, the underlying mechanism isn’t well understood, but there seems to be a problem with how the brain receives pain signals.

Generally speaking, individuals have low levels of serotonin, which is involved in inhibiting pain signals, and elevated levels of substance P, and nerve growth factor, which are involved in propagating pain signals.

Together, these are thought to play a role in the hypersensitivity to pain, which hints that fibromyalgia might be a condition of central sensitization.

Sources

  1. "Robbins Basic Pathology" Elsevier (2017)
  2. "Role of Nerve Growth Factor in Pain" Pain Control (2015)
  3. "Spinal Cord Mechanisms of Chronic Pain and Clinical Implications" Current Pain and Headache Reports (2010)
  4. "Fibromyalgia Syndrome: Etiology, Pathogenesis, Diagnosis, and Treatment" Pain Research and Treatment (2012)